O
11.19
-0.43 (-3.70%)
| Penutupan Terdahulu | 11.62 |
| Buka | 11.50 |
| Jumlah Dagangan | 655,946 |
| Purata Dagangan (3B) | 1,449,154 |
| Modal Pasaran | 977,418,176 |
| Harga / Buku (P/B) | 2.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Aug 2026 |
| EPS Cair (TTM) | -2.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.30% |
| Nisbah Semasa (MRQ) | 15.22 |
| Aliran Tunai Operasi (OCF TTM) | -124.83 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.86 M |
| Pulangan Atas Aset (ROA TTM) | -27.44% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Olema Pharmaceuticals, Inc. | Bercampur | Menaik |
AISkor Stockmoo
-1.0
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 0.5 |
| Purata | -1.00 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.32% |
| % Dimiliki oleh Institusi | 98.70% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |